Unless you’ve been living under a rock for the past few years, you have undoubtedly heard about cannabidiol (CBD), or maybe even tried it. The hemp extract has been having a fantastic run, with new testimonials on its benefits coming to light almost every day, accompanied by a government that seems interested in furthering research into the compound.
The chemical is said to be a potent natural medicine, able to act against a variety of ailments ranging from high blood pressure and chronic pain to anxiety. In fact, a survey by Gallup found that a large number of Americans who use CBD do so for its anti-anxiety capabilities. It’s well known that cannabis can have a calming, relaxing effect, and cannabidiol’s effect is much stronger than that of THC.
This has made cannabidiol a promising alternative to pharmaceutical medications since they come with side effects like tremors, impaired cognition and an increased risk of falls. A new study has found that CBD may help against one of the greatest fears that plague many people, public speaking. It’s a common condition with a scientific name, glossophobia, and it can be debilitating.
Done by researchers in Brazil, the study found that CBD can, in fact, reduce anxiety levels, but it was limited to patients with Parkinson’s disease. This gives a lot of insight into CBD’s effect on the brain and how Parkinson’s can be treated. Researchers at the Federal University of Sao Carlos and the University of Sao Paulo subjected 25 people to two separate simulated public speaking tests 15 days apart.
Twenty-two of the total 24 patients were male, and a majority of them were on other medications, most commonly levodopa.
Each time, one half of the subjects were given 100mg of CBD while the other half were given a placebo. The next time, the CBD group was given a placebo while the placebo group was given CBD. Tremors are a sign of Parkinson’s, especially associated with stress, and it was significantly reduced in patients who used CBD.
“These observations suggest that CBD may be an alternative treatment for patients with Parkinson’s and anxiety. Thus, the chronic administration of CBD could be used in future studies,” the researchers wrote.
Anxiety and attendant tremors affect 40%-60% of Parkinson’s patients, and one of the goals for the study was to build off prior researcher on the matter and prove whether or not cannabidiol can calm the tremors as well as any other signs of anxiety.
It has been shown to combat inflammation of the brain, which is partly responsible for conditions such as Parkinson’s. However, researchers agree that a lot more research is needed to prove without a doubt that CBD can be effective.
Experts believe these initial findings are proof that what CBD companies like HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) have always said about the benefits of cannabidiol has always had a lot of merit.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
